Peer-reviewed veterinary case report
Heart protein tests predict survival in dogs with mitral valve disease
By Hezzell, M J et al.·Published in Journal of veterinary internal medicine·2012·Department of Veterinary Clinical Sciences, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The combined prognostic potential of serum high-sensitivity cardiac troponin I and N-terminal pro-B-type natriuretic peptide concentrations in dogs with degenerative mitral valve disease.
- Species:
- dog
Plain-English summary
A group of dogs with degenerative mitral valve disease (DMVD) were studied to see how certain blood markers could predict their survival time. Researchers found that higher levels of two markers, high-sensitivity cardiac troponin I (hscTnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), were linked to shorter survival times. Dogs with both markers elevated tended to have the worst outcomes, especially if they died from heart-related issues. Regular testing of these markers can help veterinarians better understand a dog's prognosis and tailor treatment accordingly.
People also search for: dog heart disease prognosis · elevated troponin in dogs · NT-proBNP levels in dogs
Abstract
BACKGROUND: Identification of factors associated with decreased survival in dogs with degenerative mitral valve disease (DMVD) will allow more accurate prognosis. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is negatively associated with survival in dogs with DMVD. In human patients, multimarker strategies provide superior risk stratification compared with single markers. HYPOTHESIS: High-sensitivity cardiac troponin I (hscTnI) and other clinical variables will be associated with survival time in dogs with DMVD. Measuring hscTnI and NT-proBNP in combination will be prognostically superior to measurement of either marker alone. The rate of change of these markers will vary according to cause of death. ANIMALS: Client-owned dogs (n = 202) with DMVD of varying severity and age-matched healthy control dogs (n = 30) recruited from first opinion private practice. METHODS: Prospective cohort study relating clinical variables at enrollment in dogs with DMVD to survival time (all-cause, cardiac, and noncardiac mortality). Multivariable Cox regression analysis was used to identify factors associated with survival. Measurements were obtained approximately every 6 months. Repeated measures models were constructed to assess changes over time. RESULTS: hscTnI, LVEDDN, heart rate, and age were independently associated with decreased survival time (all-cause mortality). Survival times were shortest in dogs in which both serum hscTnI and NT-proBNP were increased. hscTnI and NT-proBNP increased more rapidly in dogs that died of cardiac disease. CONCLUSIONS AND CLINICAL IMPORTANCE: Serum hscTnI has prognostic value in dogs with DMVD. Measurement of NT-proBNP and hscTnI is prognostically superior to measuring either alone. Serial measurement strategies provide additional prognostic information.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22369312/